The glucagon gene is expressed in the α-cells of the pancreatic islets, the L cells of the intestine, and specific areas of the brain (1) . Although multiple transcription factors have been proposed to regulate glucagon gene transcription, the molecular mechanisms by which glucagon gene expression is restricted to α-cells are still not known. Pancreas-specific expression of the glucagon gene is conferred by the islet-specific enhancer elements G2, G3, and G4 (2) (3) (4) (5) , while the proximal promoter element G1 is critical for α-cell-specific expression (2-4,6,7). We and others have proposed Pax-6, Cdx-2/3, large Mafs, Brain-4 and Foxa-2 as potential factors implicated in glucagon gene expression through the transactivation of the G1 element in glucagon-producing cells by transfection studies (8) (9) (10) (11) . However, the relevance and relative importance of these factors in vivo is unknown. Pax-6 has previously been reported to be expressed in the endocrine pancreas and during pancreas development as early as embryonic day 10.5 and in the adult (12, 13) . Pax-6 is critical for α-cell development and activates glucagon gene promoter constructs through the enhancer element G3 and the α-cell specific element G1 (4) . Furthermore, Pax-6 is essential for the transactivation of glucagon gene promoter constructs in the small and large intestine (14) . Nevertheless, Pax-6 is expressed in all pancreatic endocrine cells and thus cannot explain the specificity of glucagon gene expression. has been shown to interact with Cdx-2/3 and Maf-A resulting in a synergistic transactivation of the glucagon gene (9, 15) . We and others have shown that Cdx-2/3 is able to form a heterocomplex with Pax-6 on the G1 element using InR1G9 glucagon-producing cell nuclear extracts and strongly activates gene transcription by transfection assays (15) . Nevertheless, the expression of Cdx-2/3 in α-cells is not established. Although Cdx-2/3 has been reported to be present in α-cells of the adult mouse pancreas by immunocytochemistry (16) , it is absent from the adult rat and human α-cells as well as from glucagonomas (10, 17) . Similarly, the expression of the large Mafs in the α-cells is controversial. Although Maf-A is specifically expressed in pancreatic β-cells (18, 19) , the expression of Maf-B and c-Maf in insulin-and glucagon-producing cells has generated opposing results. It has, indeed, been reported by Artner et al that Maf-B is expressed in mouse α-and β-cells during development but only in α-cells in the adult islets while c-Maf is not expressed at any stage (20) . Others have found that c-Maf but not Maf-B is expressed in α-cells (19) . Functionally, Maf-B or c-Maf deficient mice show an important reduction in both insulin-and glucagon-positive cells throughout development indicating a significant role of Maf-B and c-Maf in differentiation, replication and/or survival of endocrine precursor cells (21, 22) . Brain-4 and Foxa-1/Foxa-2 have also been shown to activate glucagon gene expression and to be expressed in the α-cells. Brain-4 is specifically expressed in α-cells throughout development and in the adult and has been proposed as a candidate for α-cell specific expression of the glucagon gene (10, 23) ; however mutant mice lacking Brain-4 have no developmental and functional defect of the α-cells raising doubts on the relevance of Brain-4 in glucagon gene expression (23) . Foxa-1 and Foxa-2 have been proposed to regulate glucagon gene expression by binding to G1 and G2 of the rat glucagon promoter (11) . Nevertheless, the binding site of Foxa-1 and 2 on G1 is overlapping with Pax-6 and overexpression of these factors in α-cells results in an inhibition of Pax-6 induced expression of the glucagon gene suggesting an inhibitory role of these factors on G1-mediated transactivation. The aim of this study was to better define and characterize the transcription factors interacting with G1 involved in the α-cell specific expression of the glucagon gene. We show here by ChIP analyses that Pax-6, Cdx-2/3, Maf-B and c-Maf interact with the glucagon gene promoter in InR1G9 cells while only Pax-6, Maf-B and c-Maf do in α-TC1 cells, suggesting that neither Cdx-2/3 nor Brain-4 are necessary for glucagon gene expression. Furthermore, while both Maf-B and c-Maf are expressed in the islets, Cdx-2/3 mRNA is expressed at very low levels in the embryonic mouse pancreas and the protein is not detected by either immunocytochemistry or Western blot analyses. Functionally, Pax-6 and c-Maf are the most potent transactivators of the glucagon gene promoter compared to Pax-6/Cdx-2/3 or Pax-6/Maf-B. We show by specifically silencing the expression of c-Maf, Maf-B and Cdx-2/3 by siRNA that c-Maf seems to be the critical partner of Pax-6 to activate endogenous glucagon gene expression. Finally, we demonstrate that c-Maf interacts with the glucagon gene promoter in adult mouse islets indicating involvement of cMaf on glucagon gene transcription in vivo.
EXPERIMENTAL PROCEDURES
Cell culture-The glucagon-producing hamster InR1G9 (24) and mice α-TC1 cells (25) as well as the non-islet Syrian baby hamster kidney (BHK21) cell lines were grown in RPMI 1640 (R-6504, Sigma, Basel, CH) supplemented with 5 % fetal bovine serum and 5 % newborn calf serum, 2 mM glutamine, 100 units/ml of penicillin and 100 µg/ml of streptomycin. Total  RNA was isolated from mouse embryonic and  adult pancreas, mouse intestine, α-TC1 and  InR1G9 cell lines using Trizol Reagent  (Invitrogen Life Technologies, Gaithersburg,  MD) according to the manufacturer's specifications. First-strand cDNA synthesis, from 1 µg of total RNA, was performed with random hexamer primers and Superscript II Reverse Transcriptase (Invitrogen) as recommended by the supplier. cDNA obtained from mouse pancreas and cell lines were analyzed by semiquantitative PCR using Goldstar (Eurogenetech, Brussels, Belgium) DNA polymerase as recommanded by the provider. PCR amplifications were analyzed on ethidium bromide-stained 3 % agarose gels. Real-time PCR were performed for glucagon and TBP (TATA box binding protein) gene expression in glucagon-producing cell lines using QuantiTect SYBR Green kit (Qiagen, Basel, CH) and LightCycler (Roche Diagnostics, Rotkreuz, CH). For quantification, a standard curve was systematically generated with four different amounts of purified target cDNA. Each assay was performed in duplicate and validation of the real time PCR runs was assessed by evaluation of the melting temperature of the products and by the slope and error obtained with the standard curve. The analyses were performed using the Light-Cycler software (Roche Diagnostics, Rotkreuz, CH). Results were corrected by TBP mRNA levels.
RNA preparation and RT-PCR Analysis-
Mouse islets purification-Mouse pancreatic islets were isolated as described previously (26, 27) .
Western blot analyses-Nuclear extracts were isolated as described (28, 29) from InR1G9 or BHK cells. Ten to thirty µg of each protein extract were resolved on a 10 % sodium dodecyl sulfate-polyacrylamide gel and transferred electrophoretically to polyvinylidene difluoride membranes. Immunoblotting was performed with polyclonal antibodies to rabbit Pax-6 diluted 1/1000 (generous gift from S. Saule (CNRS/UMR 146, Institut Curie Section de Recherche, France)), Cdx-2/3 diluted 1/500 (kind gift from M.German (University of California), Maf-B (#BL658, Bethyl, Montgomery, TX) or cMaf (#BL662, Bethyl) diluted 1/1000 and goat anti-rabbit IgG conjugated with horseradish peroxidase diluted 1/2000: (#sc2030, Santa Cruz, CA). The signal was detected with Super Signal West Pico Trial Kit (Pierce Chemical Co., IL). Protein loading was normalized by immunodetection of rabbit TFIIE-α diluted 1/500 (#C17, Santa Cruz). At least three independent experiments were performed with nuclear cell extracts. C-Maf detection was performed with or without c-Maf blocking peptide (#BP300-613, Bethyl). 5µg of c-Maf blocking peptide was preincubated two hours at room temperature with 1µg of specific c-Maf antibody (#BL662).
Co-immunoprecipitation and Western blot-α-TC1 cells were trypsinized, washed and resuspended in a buffer containing 10 mM Hepes pH7.9, 10 mM KCl, 0.1 mM EDTA, 0.1 mM EGTA, 2.5 mM DTT, 1.2 mM PMSF. Subsequent to a 15 minute incubation on ice, cells were lysed by the addition of 10 % NP40 and intact nuclei were sedimented by centrifugation. Buffer C containing 20 mM Hepes pH7.9, 25 % glycerol, 250 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1 mM DTT, 1.2 mM PMSF and complemented with a cocktail of protease inhibitors (Complete mini, Roche, Mannheim, Germany) was added to the pellet and incubated for 1 hour. Nuclear proteins were purified from membrane debris by centrifugation. Approximately 800 µg of nuclear extracts were incubated overnight at 4°C with a mouse anti-Pax-6 (#MAB1260, R&D system, Abingdon, UK) coupled to sheep α-mouse IgG magnetic Dynabeads® (Invitrogen). Beads were then washed extensively with Buffer C and resuspended in 50 µl Lämmli buffer. Ten to 50 µg of total nuclear extracts (input) and 20 µl out of the 50 µl of immunoprecipitate were separated on SDS-PAGE and transferred on to PVDF membrane (Amersham Biosciences). Membranes were incubated with either α-rabbit Pax-6 (S. Saule) or anti-rabbit Maf-B (#BL 658) and c-Maf (#BL 662) and subsequently with sheep α-rabbit IgG coupled to horseradish peroxidase. Signals were detected using Super Signal West Pico Trial Kit (Pierce Chemical Co. IL).
Immunohistochemistry-Cryosections of adult or embryonic mouse pancreas fixed with 4 % paraformaldehyde were treated with 0.1 % Triton X-100 and immunolabeled using polyclonal goat glucagon antibody (#N-17, Santa Cruz Biotechnology, Inc., Santa Cruz, CA) combined with polyclonal rabbit Maf-B (Santa Cruz Biotechnology, LabForce, Nunningen, Switzerland, P-20) and Cdx-2/3 (M. German) antibodies. Glucagon, Maf-B and Cdx-2/3 immunostaining were performed with confocal microscope (Zeiss LSM 510 confocal microscope (Carl Zeiss AG, Göttingen, Germany)). The percentage of colocalization of glucagon and Maf-B were calculated with the Metamorph software version 6.2r4 (Universal Imaging, Puchheim, Germany). Percentages were determined on at least 100 (e12.5, e14.5 and e17.5) to 500 glucagon-positive cells (adult) in four to five distinct pancreas sections corresponding to at least three different animals. 
Transient Transfection assays-

Promoter
analysisGlucagon promoter transactivation was studied after transfection of -292 to +50 bp sequence of the 5'-flanking region of the rat glucagon promoter (-292GluCAT) in BHK-21, InR1G9 and α-TC1 cell lines. Glucagon promoter activities were analyzed by chloramphenicol acetyl transferase (CAT) activity as previously described (32) . Cells were cotransfected with either a plasmid containing the human placental alkaline phosphatase gene (pSV2A-PAP) or the luciferase gene (RSV-Luc, Promega, Wallisellen, Switzerland), driven by the simian virus 40 early promoter, to monitor transfection efficiency. Quantification of acetylated and nonacetylated forms was done with a PhosphorImager (Molecular Dynamics, Sunnyvale, CA). Placental alkaline phosphatase and luciferase activities were measured by spectrophotometry and luminometry (Labsystem), respectively. A minimum of three independent transfections were performed, each of them carried out in duplicate.
Electrophoretic mobility shift assays (EMSAs)-
EMSAs were performed using the -100 to -49 sequence of the 5'-flanking region of rat glucagon promoter corresponding to the G1 element (5'-CAAAACCCCATTATTTACAGAT GAGAAATTTATATTGTCAGCGTAATATCT -3') and nuclear extracts from BHK-21 cells overexpressing either mouse Pax-6 (p46) (subcloned in the laboratory), hamster Cdx-2/3 (kindly provided by Dr. M. German (University of California, San Francisco, CA)), mouse Maf-B or mouse c-Maf full length proteins (generous gift by Dr. R. Stein (Vanderbilt University Medical Center, Nashville, TE)), respectively. EMSA reactions contained 20 mmol/l Hepes, pH 7.9, 5 mmol/l MgCl 2 , 0,5 mmol/l EDTA, 50 mmol/l KCl, 1 mmol/l DTT, 6.25 % glycerol, 1 µg BSA, 2 µg salmon sperm DNA and 2 µg poly(dIdc-dIdC) as described previously (5) with nuclear protein extracts (15-25 µg of proteins) and approximately 50 000 cpm of 5'-end 32 Plabeled oligonucleotide probe. Anti-Pax-6 (serum 13) and anti-Cdx-2/3 antibodies were generously provided by Drs S. Saule (CNRS/UMR 146, France) and M. German (University of California, San Fransisco), respectively. Anti-Maf-B (#BL658) and anti-cMaf (#BL662) antibodies were purchased at Bethyl (Bethyl Laboratories inc., Montgomery, TX).
Chromatin immunoprecipitation assay (ChIP)-
ChIP assays were performed according to Orlando et al (33) . Briefly, formaldehydecrosslinked chromatin extracts were prepared from InR1G9 and α-TC1 cells and fragmented by enzymatic digestion (Enzymatic shearing kit, Active Motif Europe, Belgium). Fifty µg (InR1G9 and α-TC1 cells) or twenty µg (adult mouse islets) of chromatin extract were first precleared with Protein A Sepharose beads (CL-4B, Pharmacia Biotech AB, Uppsala, Sweden) for 1h. After centrifugation, supernatants were incubated overnight at 4°C with 8 µg of antiPax-6 (serum 13), anti-Maf-B (#BL658, Bethyl), anti-c-Maf (#BL662, Bethyl), anti-Cdx-2/3 (M.German, University of California, San Fransisco), anti-Brain-4 (JF.Habener, Harvard University, Boston) and α-acetyl-Histone H4 antibodies (#06-866, Upstate, Lake Placid, NY) as well as rabbit IgG (#sc-2027, Santa Cruz). The immunoprecipitated DNA/protein complexes were bound to Protein A Sepharose beads after 3h of incubation at 4°C and washed in a low salt buffer, high salt buffer, LiCl buffer and Tris-EDTA buffer in succession as described by Duong et al (34) . Proteins were eliminated using proteinase K (200 µg, Applichem) in the presence of 10 % SDS by overnight incubation at 37°C. After phenol extraction, the DNA was precipitated, suspended in water and used as a template for PCR. The set of PCR primers used for analysis of binding on the glucagon gene proximal promoter (corresponding to G4-G1 box) in InR1G9 cells were 5'-GACTAGGCTCATTTGACGTC-3' and 5'-ATGGAAAGGGCAGTTTGGAG-3'; the two set of primers used for α-TC1 cells and mouse adult islets were 5'-CAAAGCGAGTGGGTGAGTG-3' and 5'-GCCACGCAGATATTACGCTG-3' and equally 5'-CAGCGTAAAAAGCAGATGAGC-3' and 5'-AGGCTGTTTAGCCTTGCAGAT-3'. PCR products were verified on ethidium bromide-stained 3% agarose gels and analyzed by real-time PCR using a Light-Cycler (Roche Diagnostics, Rotkreuz, CH).
RNA interference-Two different specific sequences of siRNA were designed by Qiagen for Cdx-2/3 and Stealth siRNA by Invitrogen for Maf-B, c-Maf and Pax-6 against hamster mRNA sequences. Appropriate scrambles were obtained at the same time (percentage of GC content identical to Pax-6, Maf-B, c-Maf and Cdx-2/3 siRNA). InR1G9 cells grown in 6-well plates were transfected with 100nM of siRNA using 5 µl Lipofectamine 2000 (Invitrogen, Carlsbad, CA) as recommended by the supplier. Transfections were performed twice sequentially. Total RNA and nuclear extract were isolated 48 h after transfection as described above in experimental procedures.
Data analysis-Data are presented as means ± SEM and analyzed by Student-t test. A p value of less than 0.05 was considered to be statistically significant.
RESULTS
Specific expression of the glucagon gene in rat pancreas requires the presence of the G1 element which contain putative binding sites for Pax-6, Cdx-2/3, Mafs and Brain-4 ( Fig.1 ). Since the expression of Pax-6 and Brain-4 in α-cells have been clearly documented during pancreas development and adulthood (10,13,23), we studied the expression of Cdx-2/3, Maf-B and cMaf which have all been proposed to activate glucagon gene transcription along with Pax-6. We first examined the expression of Cdx-2/3, Maf-B and c-Maf at different stages of pancreatic development (Fig.2) . As shown in Figure 2A , Maf-B and c-Maf mRNAs can be detected from at least embryonic day 12.5 (e12.5) until the adult stage. At all stages, Maf-B mRNA levels are much higher compared to those of c-Maf. The Maf-B/c-Maf mRNA ratio increases during development to reach around 10 in the adult. Large Mafs mRNAs are also present in the hamster and mouse glucagon-producing cell lines InR1G9 and α-TC1, respectively. By contrast, Cdx-2/3 mRNA was hardly detected from total mouse pancreas during development and in the adult islets, although southern-blots of the RT-PCR samples using a specific Cdx-2/3 cDNA probe revealed the presence of Cdx-2/3 mRNA at all the different developmental stages (data not shown). However, we found substantial Cdx-2/3 mRNA levels in InR1G9 cells but not in α-TC1 cells. We then performed immunohistochemistry on mouse pancreas sections prepared at e12.5, e14.5, e17.5 and in the adult (Fig 2B) . We could not detect Cdx-2/3 at any stage of development, nor in the adult, whereas it was present in the adult mouse intestine, used as a positive control. Cdx-2/3 was not detected either by Western blot of adult islet nuclear extracts while it was present in InR1G9 cells (data not shown). We also assessed for the presence of the transcription factor Maf-B in glucagon-positive cells (Fig.2B) . Maf-B is present as soon as e12.5 and can be detected until the adult stage. At e12.5, only about 10 % of the glucagon-positive cells expressed Maf-B. This percentage increased progressively until the adult stage to 88 % (Fig.2B) . To detect c-Maf, we also used two antibodies (M-153 and BL662); the BL662 antibody was raised against mouse c-Maf and reported to be specific, while M-153 was not specific as it could also detect both Maf-B and Maf-A proteins (data not shown and (19)). However, we could not detect c-Maf in pancreas sections using the specific BL662 antibody as reported by others (18, 20) . To further evaluate the presence of c-Maf and Maf-B in α-cells, we performed Western blots of α-cell lines and adult mouse islet protein extracts; both Mafs were detected in α-TC1 cells and adult islets, whereas only Maf-B was found in InR1G9 cells (Fig.2C-D) . We hypothesize that the BL662 antibody raised against mouse c-Maf is not able to recognize hamster c-Maf by Western blots. Overall, our results indicate that Cdx-2/3 is not required and may be dispensable for glucagon gene expression as it is absent from α-TC1 cells and not or very weakly expressed in mouse pancreas during development and in the adult, although we cannot exclude formally a role of Cdx-2/3 at some stage of development in glucagon gene expression. By contrast, Maf-B and probably c-Maf are expressed throughout development and in the adult α-cells; however, since a significant percentage of glucagonproducing cells do not express the large Mafs at least during development, these factors may not be absolutely required for glucagon gene expression, although it is possible that low amounts of large Mafs precluding detection by immunocytochemistry are present in all α-cells. To investigate the involvement of Pax-6, Cdx-2/3, Maf-B and c-Maf on glucagon gene expression, we first performed ChIP assays on α-pancreatic cell lines to determine the in vivo binding of these transcription factors to the glucagon promoter (Fig.3) . We also investigated the binding of Brain-4, an α-cell-specific transcription factor present in both InR1G9 and α-TC1 cells which has been proposed to bind G1 (10) . In the InR1G9 hamster cell line, Pax-6, Maf-B, c-Maf and Cdx-2/3 were found to strongly interact with the glucagon promoter but not Brain-4 (Fig.3A) . Similar results were obtained with α-TC1 cells (Fig.3B) , although no interaction of Cdx-2/3 was observed in agreement with the fact that it is not expressed in these cells. These data indicate that Pax-6, Maf-B and c-Maf interact with G1 as well as Cdx-2/3 in InR1G9 cells but not Brain-4. To further characterize the respective transcriptional effects of Pax-6, Cdx-2/3 and large Mafs on the glucagon gene promoter, we performed transient transfections with the rat glucagon gene promoter (-292/+50), linked to the CAT gene with expression plasmids containing full-length cDNAs of these transcription factors in the BHK-21 cell line (Fig.4) . We first quantified the respective levels of Maf-B, c-Maf and Cdx-2/3 in BHK nuclear extracts after transfection; after correction for TFIIE-α, levels of Maf-B and c-Maf were equal but fourfold higher than levels of Cdx-2/3 (data not shown). Pax-6, Cdx-2/3, Maf-B and c-Maf can all activate glucagon gene promoter activity by 12.4, 6.6, 7.7 and 19.6-fold, respectively. Since both Cdx-2/3 and Maf-A have been proposed to interact with Pax-6, we performed transfection studies with Pax-6, Cdx-2/3 and the large Mafs in combination. When Pax-6 and Cdx-2/3, Pax-6 and Maf-B or Pax-6 and c-Maf cDNAs were cotransfected, we observed a synergistic activation on glucagon gene promoter activity reaching 38.3, 83.9 and 141.1-fold respectively (Fig.4) . No additional activity was obtained with the combination of all these factors nor did we observe any additive or synergistic activity between Cdx-2/3 and Maf-B or c-Maf. In addition cotransfection of the coactivator p300 cDNA with Pax-6/Cdx-2/3 or Pax-6/large Maf did not increase further glucagon gene promoter transactivation (Fig.4) . Taken together, these results indicate that c-Maf is a stronger activator of the glucagon gene promoter compared to Maf-B or Cdx-2/3 and induces the strongest activation when combined with Pax-6. However, taken into account that levels of Cdx-2/3 are four fold lower than those of Maf-B and c-Maf, it is possible that the complexes Pax-6/c-Maf and Pax-6/Cdx-2/3 have similar transcriptional capacities. To investigate the respective binding affinity of Pax-6, Cdx-2/3 and the large Mafs to G1 as well as their protein-protein-DNA interactions, we performed electromobility shift assays (EMSA) with the G1 element of the rat glucagon gene promoter and nuclear extracts from BHK-21 cells overexpressing the Pax-6, Cdx-2/3 or the large Maf proteins (Fig.5) . As previously described Pax-6 and Cdx-2/3 were able to bind the G1 element both alone and together as verified by antisera raised against the Pax-6 or Cdx-2/3 proteins (Fig.5A) . Maf-B and c-Maf were both able to interact with G1 (Fig.5B) . When extracts from BHK-21 cells overexpressing Pax-6 were added to the extracts containing either Maf-B or c-Maf, complexes with higher electrophoretic mobility appeared (Fig.5B) . To verify the nature of these complexes, antibodies raised against Maf-B, cMaf and/or Pax-6 proteins were used. The slow migrating complexes obtained with Pax-6/Maf-B and Pax-6/c-Maf were supershifted by the respective antibodies, indicating that Maf-B and c-Maf can interact together with Pax-6 on G1. Furthermore, both Maf-B and c-Maf can directly interact with Pax-6 independently of DNA binding as assessed by co-immunoprecipitation (Fig.5E) . We then investigated the binding affinity of Pax-6, Cdx-2/3, Maf-B and c-Maf alone (Fig.5C ) or in combination on G1 (Fig.5D) . We incubated labeled G1 with a constant amount of BHK-21 nuclear extracts overexpressing Pax-6, Cdx-2/3, Maf-B or c-Maf individually and increasing amounts of nonlabeled G1 probe. Pax-6 had the highest while Cdx-2/3 had the lowest affinity for G1; large Mafs had an intermediate affinity. We then tested the relative binding affinity of the complexes of Pax-6/Cdx-2/3, Pax-6/Maf-B and Pax-6/c-Maf for G1 (Fig.5D) . Despite the relative low affinity of Cdx-2/3 for G1, Pax-6/Cdx-2/3 presented the highest affinity (two fold higher) compared to Pax-6/large Mafs. These results indicate that Pax-6 alone or in combination with Cdx-2/3 has the highest affinity for G1, suggesting that Cdx-2/3, even at low levels, might still play a role in glucagon gene transcription dimerized to Pax-6. To investigate the functional role of Cdx-2/3 and Maf proteins on glucagon gene expression, we used dominant negative forms of these proteins called Cdx-2/3/aa180-313 pcDNA 3.1-myc/his (DN-Cdx2/3) and MafA/aa135-359 pcDNA 3.1 (DN-MafA) (generous gifts from Dr Jin T. and Dr Stein R. respectively) (Fig.6-7) which bind G1 as effectively as the wild type forms (data not shown). Since Maf-A binds G1 as well as Maf-B and c-Maf, we used for convenience its dominant negative form to compete for Maf-B or c-Maf 7 binding.
We performed cotransfection experiments in BHK-21 cells using fragments of the 5' flanking sequence of the rat glucagon gene promoter (-292/+50) linked to the CAT reporter gene and SV40-driven expression vectors containing cDNAs encoding Pax-6, Cdx-2/3, Maf-B or the dominant negative forms of Cdx-2/3 and Maf-A. DN-Cdx2/3 and DN-MafA were both able to suppress the synergistic transcriptional activity obtained with Pax-6 and Cdx-2/3 or Maf-B/c-Maf, respectively (Fig.6) . Interestingly, DN-Cdx2/3 was also able to inhibit Pax-6/large Maf effects on glucagon promoter activity as effectively as DN-MafA while DNMafA was similarly able to suppress Pax-6/Cdx-2/3 action suggesting that either DN forms can compete with both Pax-6/Cdx-2/3 and Pax-6/large Mafs complexes for binding and/or protein-protein interactions. We then tested the effects of DN-Cdx2/3 and DN-MafA overexpression on glucagon gene promoter activity in the two α-pancreatic cell lines (Fig.7) . Cotransfection experiments were performed using the rat glucagon promoter (-292/+50) and DN-Cdx2/3 or DN-MafA. We observed in both cell lines an inhibition of transcriptional activity with both dominant negative factors reaching 60 % and 40 % in InR1G9 and α-TC1 cells respectively with DN-MafA (Fig.7A-B ) and 50 % in InR1G9 cells with DN-Cdx2/3 (Fig.7A) . Interestingly, despite the absence of Cdx-2/3 in α-TC1 cells, overexpression of DN-Cdx2/3 resulted in a marked inhibition of glucagon promoter activity (Fig.7B) suggesting again competition between large Mafs and Cdx-2/3 binding to G1 and/or disruption of the Pax-6/large Maf complex. We next investigated the effects of DN-Cdx2/3 and DN-MafA on endogenous glucagon gene expression in InR1G9 cells (Fig.7C) . Overexpression of both negative form of Cdx-2/3 and Maf-A led to a drastic diminution of glucagon mRNA levels, respectively of 60 % and 40 %. To more specifically investigate the functional role of Pax-6, the large Mafs and Cdx-2/3 on glucagon gene expression, we used siRNA to silence the expression of Pax-6, Cdx-2/3, Maf-B and c-Maf in InR1G9 cells, used here because of the high transfection efficiency. Transfection of specific siRNA led to significant decreases of Pax-6, Cdx-2/3, Maf-B and c-Maf mRNA levels in InR1G9 cells of about 60 %, 80 %, 50 % and 50 %, respectively (Fig.8A) and Pax-6, Cdx-2/3 and Maf-B proteins were diminished by 75 %, 80 % and 60 %, respectively as assessed by Western blots analyses (Fig.8B) . However, hamster c-Maf was not detected with the BL662 raised against c-Maf as mentioned previously. We then investigated endogenous glucagon gene expression in InR1G9 cells after siRNA transfection. Inhibition of Pax-6 expression led to a 45 % decrease of endogenous glucagon gene expression (Fig.8C) . By contrast, specific silencing of Cdx-2/3 did not affect glucagon gene expression indicating that Cdx-2/3 is not critically involved on basal glucagon gene transcription in α-pancreatic cell lines. Inhibition of c-Maf expression led to a 34 % decrease in glucagon mRNA levels, while inhibition of Maf-B was not accompagnied by any effect, suggesting that c-Maf but not Maf-B is involved in the control of basal glucagon gene expression in InR1G9 cells. Finally, we transfected different combinations of siRNAs and observed that inhibition of glucagon gene expression occurred only in the presence of siRNAs against Pax-6 or c-Maf and that simultaneous inhibition of Pax-6 and c-Maf did not lead to any additional inhibitory effects. Finally, to assess c-Maf involvement on glucagon gene expression in vivo, we performed c-Maf binding analyses in mouse adult islets by ChIP analyses using two different sets of glucagon gene promoter primers; we clearly show that c-Maf interacts with the glucagon gene promoter in vivo (Fig.9) . We conclude that Pax-6 and c-Maf are able to bind the glucagon gene promoter and are critical for basal glucagon gene expression.
DISCUSSION
We show here that Pax-6 and c-Maf are the most likely candidates to transactivate the glucagon gene promoter through G1. This is based on a combination of both expression and functional studies. G1 is a large 50 bp control element with three potential binding sites, a distal site to which Pax-6 and Brain-4 have been reported to bind and two proximal sites for Cdx-2/3 and the large Mafs. The binding sites for Pax-6 and Brain-4 are overlapping (10, 15) . Pax-6 is detected in glucagon-producing cells of the mouse embryonic pancreas at day 10.5 and in all pancreatic endocrine cells at later stages in development (12, 13, 35) . Pax-6 interacts with G1 and transactivates the rat glucagon gene promoter both alone and synergistically with Cdx-2/3 and the large Mafs (9,15). Brain-4 is also expressed in the developing and adult α-cells from day 9.5 and is able to activate glucagon gene promoter constructs through G1 (10, 36) . Furthermore, Brain-4 is specifically expressed in α-cells and not in other islet cell types. However by contrast to the dramatic effects observed in Pax-6 mutant mice where α-cells are lacking, the absence of Brain-4 in homozygous mutant mice does not result in any abnormality in α-cell development or function (23) , suggesting that Pax-6 is a more likely candidate than Brain-4 in the activation of the α-cell-specific element G1. In agreement with this hypothesis, we find by ChIP analyses that Pax-6 but not Brain-4 interacts in vivo with G1 while both factors are present in InR1G9 cells. Furthermore, the functional relevance of Pax-6 in glucagon gene expression is supported by the significant decrease in endogenous glucagon mRNA levels in the presence of siRNA specifically silencing Pax-6 gene expression. We thus conclude that Pax-6 binds the distal binding site of G1 and is functionally critical for glucagon gene expression. Cdx-2/3 and the large Mafs have been proposed to interact more proximally on the G1 element and to activate glucagon gene constructs synergistically with Pax-6 (8,9,15). Their respective core binding sites are adjacent but it is not known whether their sites are overlapping and their binding mutually exclusive. Furthermore, their functional relevance on endogenous glucagon gene expression has not been determined. Indeed only overexpression studies have been performed previously (7, 19, 20, 37, 38) . Cdx-2/3 however is unlikely to play a critical role in glucagon gene expression. Our studies show that the Cdx-2/3 gene is expressed at very low levels in the developing pancreas and in the adult islets. Furthermore, it is undetectable by immunocytochemistry as it has previously been reported in the adult rat and human α-cells as well as in glucagonomas (17) . We also find that in α-TC1 cells, the Cdx-2/3 gene is not expressed clearly indicating that it is dispensable for glucagon gene expression. Finally, silencing Cdx-2/3 gene expression in InR1G9 cells does not result in any change in glucagon mRNA levels despite the fact that Cdx-2/3 can bind to the glucagon gene promoter as assessed by ChIP analyses. The discrepancy between the capacity of Cdx-2/3 to bind the glucagon promoter in vivo and the absence of functional consequences when it is partially suppressed remains unexplained. We conclude however that Cdx-2/3 is expressed at very low levels in α-cells and unlikely to play a major role in glucagon gene expression. The large Maf subfamily has multiple members including Maf-A, Maf-B, c-Maf and Nrl. Although Maf-A has been clearly shown to be specifically expressed in β cells (18, 19) , controversial data exist on the respective distribution of Maf-B and c-Maf in α-and β-cells. It was first suggested that Maf-B was expressed more in α-than β-cells and c-Maf was present at low levels (18) . Maf-B and c-Maf were then shown to be expressed in pancreatic α-cell lines and c-Maf to be specific for α-cells in the mouse (19) . More recent data indicate that Maf-B is expressed as early as e10.5 and in both mouse glucagon-and insulin-producing cells although not uniformly and becomes restricted to α-cells in the adult and a few β-cells (20, 39) . It is to be noted that in the porcine pancreas, Maf-B is only expressed in β cells in the adult. C-Maf by contrast is present in both cell types during development and in the adult in the mouse (39) and porcine pancreas (40) although it has been proposed that c-Maf is not expressed in pancreatic endocrine cells (20) . We find that Maf-B is expressed at much higher levels than cMaf during mouse pancreatic development and in the adult. The same quantitative observation is found in glucagon-producing cell lines. We could not assess the presence and cell type distribution of c-Maf by immunocytochemistry since the different α-c-Maf antibodies available were either non-specific or did not generate any signal. By contrast, by Western blot analyses the anti-c-Maf BL662 antibody clearly demonstrated the presence of c-Maf in a reproductible pattern of bands in α-TC1 cells and mouse adult islets confirming previous data (39) . Both Maf-B and c-Maf are able to bind G1 in vitro and in vivo as indicated by EMSA and ChIP analyses; they bind with the same affinity both alone and in complexes with Pax-6. Indeed both Maf-B and cMaf can directly interact with Pax-6 in the presence or absence of G1 as shown by EMSA and immunoprecipitation studies. Such an interaction between Pax-6 and the large Mafs was previously suggested for Maf-A (9). The transcriptional capacity of c-Maf was however significantly stronger compared to Maf-B in the presence or absence of Pax-6, suggesting that the large Mafs have clear functional differences. Similar observations have been previously reported for the αA-crystallin gene promoter (41) . Furthermore, silencing of c-Maf but not Maf-B in InR1G9 cells specifically affected endogenous glucagon mRNA levels indicating that these factors may not be redundant at least in glucagon cell lines. We cannot exclude, however, that our results are somewhat biased by the fact that a 60 % inhibition of the relatively abundant Maf-B might not be sufficient to affect glucagon gene expression while the same decrease in c-Maf which is expressed at low levels results in clear effects; in the latter experiments however, Maf-B was unable to compensate for the decrease of c-Maf. We propose that by analogy to the crystallin genes in the lens, Pax-6 might open the chromatin structure, activate c-Maf gene expression and along with c-Maf in turn, activate glucagon gene expression (41) . These data then raise several questions, and more importantly the role of Maf-B which is much more abundant in the mouse α-cells than c-Maf and which is able to bind the glucagon gene promoter in vivo at e18.5 (21) . Is Maf-B only implicated in endocrine cell development? Or alternatively in the regulated and not basal glucagon gene expression? Investigations of Maf-B or c-Maf deficient mice clearly showed a key role of large Mafs in the production of mature α-and β-cells (21, 22) . Furthermore, Maf-B is able to form homodimers through its leucine repeat structure and heterodimers with c-Maf, small Mafs and Fos (42) suggesting a potential role in the regulated expression of the glucagon gene. Nevertheless, to our knowledge, there is no clear evidence that Maf-B can activate glucagon gene transcription despite its in vivo binding. Indeed, a previous study showed that inhibition of Maf-B expression in α-TC cells did not lead to change of the rat glucagon promoter activity (19) , similarly to the results of our siRNA experiments (Fig.8) . Furthermore, a preliminary study showed that injection of specific c-Maf siRNA in mouse led to a decrease in glucagon gene expression suggesting that c-Maf can transactivate the glucagon gene expression (43) . Taken together, we show here that c-Maf is clearly involved in basal glucagon gene expression in InR1G9 cells and is able to bind the glucagon gene promoter in mouse pancreatic islets (Fig.9) . To verify whether the Maf and Cdx-2/3 binding sites are overlapping, we analysed the effects of dominant negative forms of the large Mafs or Cdx-2/3 on glucagon gene transcription in both glucagon-and non glucagon-producing cells. Overexpression of DN-Cdx2/3 and DN-MafA markedly decreased glucagon promoter activity and glucagon gene expression in InR1G9 cells. We observed similar results in α-TC1 cells which do not express Cdx-2/3, thus suggesting that the large Mafs and Cdx-2/3 binding sites are overlapping and that there is competition between the large Mafs and Cdx-2/3 to bind G1. These data also illustrate the critical importance of the distal (Pax-6 binding site) and proximal elements of G1 for glucagon gene expression. Although c-Maf is expressed in α-cells, it is also found in β-cells as well as Pax-6. We previously proposed the hypothesis that glucagon gene expression results from a default pathway (1) . The absence of the β-cell specific transcription factors, such as Pdx-1, Pax-4 and Nkx-6.1 through the action of Arx and other factors during development would allow for the glucagon gene to be expressed and for the differentiation of the α-cell in the presence of islet-specific factors. The absence of the-β cell specific factors Pax-4 or Pdx-1 in knock-out mice results in an increase in α-cells and a large number of cells coexpressing glucagon and insulin (44, 45) . We have also shown that ectopic expression of Pax-4 or Pdx-1 in glucagonproducing cell lines inhibit basal transcription of the glucagon gene promoter by 60 to 90 %. Both Pax4 and Pdx-1 are able to bind to the Pax-6 binding site with higher or similar affinity compared to Pax-6. In addition expression of Pdx-1 in glucagon-producing cells inhibits endogenous glucagon gene expression (46, 47) . Finally, overexpression of a dominant negative form of Pdx-1 in insulin-producing cells leads to coexpression of insulin and glucagon in the same cell suggesting an inhibitory role of Pdx-1 on glucagon gene expression (48) . More recently, Nkx-6.1 has also been shown to play an inhibitory role on glucagon gene expression (49) through competition with Pax-6 (50). We thus conclude that α-cell-specific expression of the glucagon gene is conferred by two potential mechanisms, the interaction of Pax-6 and c-Maf on G1, and the absence of β-cell specific transcription factors such as Pax-4, Pdx Binding was also analyzed by real-time PCR with a Light-Cycler (Roche Diagnostics). To confirm cMaf binding a second set of glucagon gene promoter primers were used and gave identical results (data not shown). Binding intensity data are expressed relative to IgG immunoprecipitation (nonspecific binding) and are presented as the mean ± SEM for at least three independent experiments. * indicates statistical significance with p<0.05 value using a Student-t test. Figure 5B Relative Glucagon mRNA expression Relative binding intensity * *
